Your browser is no longer supported. Please, upgrade your browser.
OTLK Outlook Therapeutics, Inc. monthly Stock Chart
Outlook Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.54 Insider Own15.60% Shs Outstand47.90M Perf Week-8.72%
Market Cap170.00M Forward P/E- EPS next Y-0.51 Insider Trans4.41% Shs Float39.94M Perf Month6.25%
Income-50.80M PEG- EPS next Q-0.11 Inst Own4.90% Short Float5.83% Perf Quarter103.93%
Sales6.40M P/S26.56 EPS this Y79.70% Inst Trans-0.31% Short Ratio0.79 Perf Half Y47.12%
Book/sh-0.43 P/B- EPS next Y10.70% ROA-274.80% Target Price- Perf Year-36.45%
Cash/sh0.04 P/C36.17 EPS next 5Y- ROE274.00% 52W Range0.50 - 2.38 Perf YTD130.51%
Dividend- P/FCF- EPS past 5Y22.80% ROI2576.60% 52W High-42.86% Beta0.37
Dividend %- Quick Ratio0.40 Sales past 5Y-2.10% Gross Margin- 52W Low172.55% ATR0.13
Employees14 Current Ratio0.40 Sales Q/Q- Oper. Margin- RSI (14)47.42 Volatility8.11% 9.08%
OptionableNo Debt/Eq- EPS Q/Q62.80% Profit Margin- Rel Volume0.58 Prev Close1.38
ShortableYes LT Debt/Eq- EarningsMay 27 AMC Payout- Avg Volume2.93M Price1.36
Recom1.60 SMA20-5.52% SMA507.90% SMA20037.08% Volume1,751,779 Change-1.45%
Sep-11-19Initiated Ladenburg Thalmann Buy $9
May-16-19Initiated Oppenheimer Outperform $12
Apr-22-19Initiated Ascendiant Capital Markets Buy
Jul-17-20 08:05AM  
Jul-07-20 08:05AM  
Jun-25-20 09:43AM  
Jun-23-20 08:00AM  
Jun-17-20 08:05AM  
Jun-11-20 08:05AM  
Jun-10-20 08:12PM  
Jun-09-20 08:05AM  
Jun-03-20 08:05AM  
May-26-20 08:05AM  
May-20-20 08:39AM  
May-15-20 08:00AM  
Apr-21-20 08:05AM  
Apr-16-20 09:16AM  
Apr-15-20 08:35AM  
Apr-14-20 08:05AM  
Mar-19-20 09:32AM  
Mar-05-20 08:00AM  
Feb-26-20 02:26PM  
Feb-25-20 09:15AM  
Feb-24-20 08:00AM  
Feb-18-20 01:28PM  
Feb-14-20 08:00AM  
Feb-04-20 08:00AM  
Jan-28-20 08:00AM  
Dec-26-19 08:00AM  
Dec-24-19 07:24AM  
Dec-23-19 09:00AM  
Dec-19-19 08:00AM  
Dec-03-19 08:00AM  
Nov-13-19 10:44AM  
Sep-11-19 08:00AM  
Aug-27-19 08:00AM  
Aug-20-19 08:00AM  
Aug-14-19 04:15PM  
Jul-19-19 12:39PM  
Jul-18-19 12:05PM  
Jul-16-19 08:00AM  
Jun-03-19 08:57AM  
May-24-19 12:50PM  
May-20-19 09:02AM  
May-17-19 03:17PM  
May-16-19 09:48AM  
May-15-19 08:00AM  
Apr-26-19 08:00AM  
Apr-10-19 09:00AM  
Apr-01-19 08:00AM  
Mar-15-19 09:00AM  
Mar-05-19 08:00AM  
Mar-01-19 08:00AM  
Feb-14-19 08:00AM  
Feb-13-19 11:45AM  
Feb-01-19 09:15AM  
Jan-22-19 09:00AM  
Jan-02-19 09:15AM  
Dec-18-18 09:00AM  
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was founded in 2010 and is headquartered in Cranbury, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Syntone Ventures LLC10% OwnerJul 15Buy1.22823,0451,000,00016,823,045Jul 28 06:01 PM
BioLexis Pte Ltd.DirectorMar 23Option Exercise0.0029,358,621050,965,058Mar 23 05:35 PM
BioLexis Pte Ltd.DirectorJan 29Option Exercise0.234,657,8521,080,62221,606,437Jan 29 05:53 PM
BioLexis Pte Ltd.DirectorDec 23Option Exercise0.232,909,091674,90916,948,585Dec 30 05:14 PM